Why Shares of Medical Device Maker Endologix Are Cratering

Shares of Endologix, Inc. ELGX, a manufacturer of medical devices for the treatment of aortic disorder, are moving to the downside Monday.

What Happened: Irvine, California-based Endologix said it has initiated a voluntary Chapter 11 filing after undergoing a strategic review. The company also said it has simultaneously filed a consensual plan of reorganization supported by Deerfield Partners, its largest creditor.

The plan provides for Endologix being taken private by Deerfield, with the company expecting to emerge financially well-equipped to realize the full potential of what it said is the most advanced and innovative abdominal aortic aneurysm pipeline in the industry.

The plan would also help the company eliminate about $180 million in debt from its balance sheet on a net basis, including the $130 million owed to Deerfield , which would be converted to equity in the reorganized company. It would also gain access to new financing to the tune of $110.8 million.

Why It Matters:  The COVID-19 pandemic has hurt both the top- and bottom-line of companies, leaving some in a cash crunch.

Endologix said it believes the actions announced Monday will help it address financial challenges resulting from COVID-19 and the related delays in elective medical procedures. 

"The path we are now taking to strengthen our balance sheet and transition to private ownership will allow us to accelerate our progress with our strong patient-first business focus, an enduring spirit of innovation, and an unrelenting commitment to advancing our life-saving products supported by industry-leading evidence," CEO John Onopchenko said in a statement. 

What's Next: Endologix said it expects to finalize the process and emerge as a private company by the third quarter of 2020. The company said it fully intends to operate its business as usual during the process.

ELGX Price Action: The stock was plunging 65.34% to 27 cents at the time of publication Monday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus

Posted In: BiotechNewsPenny StocksMoversTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.